Get started
Author

Paul L. de Souza

Observed names: P L de Souza, P. L. De Souza, P. L. de Souza, P.L. de Souza, Paul L DE SOUZA, Paul L De Souza, Paul L Souza, Paul L de SOUZA, Paul L de Souza, Paul L. De Souza, Paul L. De Souza, Paul Souza, Paul de Souza
Observed institutions: Camden and Campbelltown Hospitals, The University of Sydney, City Of Hope National Medical Center, Cliniques Universitaires Saint-Luc, Box Hill Hospital, University of Virginia Health System, Gold Coast Hospital, Austin Hospital, Queen Mary Hospital, Liverpool Hospital, Nepean Hospital, Canberra Hospital, Westmead Hospital, UNSW Sydney, GlaxoSmithKline (Australia), Prince of Wales Hospital, St George Hospital, Calvary Hospital, University of Virginia Medical Center, Ingham Institute, Gold Coast Health, University of Virginia, Western Sydney University
ORCID: 0000-0002-7380-1170
Observed ORCID: 0000-0002-7380-1170
OpenAlex ID: A5110149503
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
2009 · Thomas E. Hutson, Ian D. Davis, et al. · Journal of Clinical Oncology · 295
Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study
2012 · David Goldstein, Barbara K. Bennett, et al. · Journal of Clinical Oncology · 139
PDF
Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment
2014 · Manuela Callari, Janice R. Aldrich-Wright, et al. · Progress in Polymer Science · 113
Folate Conjugation to Polymeric Micelles via Boronic Acid Ester to Deliver Platinum Drugs to Ovarian Cancer Cell Lines
2013 · Wei Scarano, Hien T. T. Duong, et al. · Biomacromolecules · 102
Risk factors for erectile dysfunction in a cohort of 108 477 Australian men
2013 · Marianne F Weber, David P Smith, et al. · The Medical Journal of Australia · 89
Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor
2008 · T. E. Hutson, I. D. Davis, et al. · Journal of Clinical Oncology · 82
Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)
2007 · T. E. Hutson, I. D. Davis, et al. · Journal of Clinical Oncology · 76
Block Copolymer Micelles with Pendant Bifunctional Chelator for Platinum Drugs: Effect of Spacer Length on the Viability of Tumor Cells
2012 · Vien T. Huynh, Jing Yang Quek, et al. · Biomacromolecules · 74
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2012 · Charles J. Ryan, Matthew Raymond Smith, et al. · Journal of Clinical Oncology · 73
The Effect of Drug Loading on Micelle Properties: Solid‐State NMR as a Tool to Gain Structural Insight
2017 · Manuela Callari, Paul L. De Souza, et al. · Angewandte Chemie International Edition · 68
PDF
Prognostic Factors in Ovarian Cancer
1992 · Paul L. de Souza, Michael L. Friedlander · Hematology/Oncology Clinics of North America · 59
Acid Degradable Cross-Linked Micelles for the Delivery of Cisplatin: A Comparison with Nondegradable Cross-Linker
2012 · Vien T. Huynh, Sandra Binauld, et al. · Chemistry of Materials · 58
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2012 · Charles J. Ryan, Matthew Raymond Smith, et al. · Journal of Clinical Oncology · 58
Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer
2010 · Paul L De Souza, Pamela J Russell, et al. · Nutrition Reviews · 43
Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer
2012 · C.F. Xu, Z. Xue, et al. · Annals of Oncology · 38
Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
2015 · Ethan M. Basch, Mark C. Scholz, et al. · Journal of Clinical Oncology · 34
AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.
2019 · John D. Powderly, Paul L. de Souza, et al. · Journal of Clinical Oncology · 32
The Effect of Drug Loading on Micelle Properties: Solid‐State NMR as a Tool to Gain Structural Insight
2017 · Manuela Callari, Paul L. De Souza, et al. · Angewandte Chemie · 25
Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer
2011 · Jan B Howes, Paul L de Souza, et al. · BMC Clinical Pharmacology · 24
PDF
A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.
2016 · Ben Markman, Paul L. De Souza, et al. · Journal of Clinical Oncology · 23
Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.
2013 · Dana E. Rathkopf, Matthew Raymond Smith, et al. · Journal of Clinical Oncology · 23
Randomized Crossover Study Evaluating the Effect of Gemcitabine Infusion Dose Rate: Evidence of Auto-Induction of Gemcitabine Accumulation
2007 · Peter Grimison, Peter Galettis, et al. · Journal of Clinical Oncology · 23
Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol™), a novel isoflav-3-ene, in patients with advanced cancer
2006 · Paul L. de Souza, Winston Liauw, et al. · Cancer Chemotherapy and Pharmacology · 23
9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer.
1997 · P L de Souza, M R Cooper, et al. · PubMed · 23
Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells
2009 · R A C McPherson, P T Galettis, et al. · British Journal of Cancer · 19
PDF
Works count: 72
Citation count: 1,736
H-index: 23
I10-index: 28
Year
Topic
Type